These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1236 related articles for article (PubMed ID: 34726500)

  • 21. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Syed YY
    Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Schultz NM; O'Day K; Sugarman R; Ramaswamy K
    J Manag Care Spec Pharm; 2020 Apr; 26(4):538-549. PubMed ID: 32020841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
    Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
    J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
    Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
    Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
    Griesinger F; Curigliano G; Thomas M; Subbiah V; Baik CS; Tan DSW; Lee DH; Misch D; Garralda E; Kim DW; van der Wekken AJ; Gainor JF; Paz-Ares L; Liu SV; Kalemkerian GP; Houvras Y; Bowles DW; Mansfield AS; Lin JJ; Smoljanovic V; Rahman A; Kong S; Zalutskaya A; Louie-Gao M; Boral AL; Mazières J
    Ann Oncol; 2022 Nov; 33(11):1168-1178. PubMed ID: 35973665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients.
    Zheng X; Fang M; Fan Y; Sun Y; Sun M; Yang A; Zhang B; Liu Q; Liu H; Zhou X; Huang T; Qin J; Wang Z; Qin M; Shen Z; Yao S; Yang J; Wang Y; Gao M
    Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38261313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive molecular pathology in metastatic thyroid cancer: the role of
    Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring
    Stargardter M; McBride A; Tosh J; Sachdev R; Yang M; Ambavane A; Mittal M; Vioix H; Liu FX
    J Med Econ; 2021; 24(1):816-827. PubMed ID: 34126842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.
    Cognigni V; Giudice GC; Bozzetti F; Milanese G; Moschini I; Casali M; Mazzaschi G; Tiseo M
    Anticancer Drugs; 2024 Jul; 35(6):559-562. PubMed ID: 38453158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
    Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
    Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
    Abraham I; Calamia M; Alkhatib N; Pondel M; MacDonald K
    J Med Econ; 2024 Jul; ():1-36. PubMed ID: 39016811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
    Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
    J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a
    Cai B; Zhou ZY; Xue W; Hazra NC; Singh M; Mishra D; Brixner D; Oderda G; Biskupiak J
    J Med Econ; 2021; 24(1):131-139. PubMed ID: 33397178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
    Nguyen VQ; Geirnaert M
    J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery, preclinical development, and clinical application of pralsetinib in the treatment of thyroid cancer.
    Locantore P; Novizio R; Corsello A; Paragliola RM; Pontecorvi A; Corsello SM
    Expert Opin Drug Discov; 2022 Feb; 17(2):101-107. PubMed ID: 34702125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
    Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
    J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer.
    Nguyen L; Monestime S
    Am J Health Syst Pharm; 2022 Mar; 79(7):527-533. PubMed ID: 34864862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pralsetinib for the treatment of non-small cell lung cancer.
    Fu XY; Dong XD; Zeng L; Ashby CR; Chen ZS; Cheng C
    Drugs Today (Barc); 2021 Sep; 57(9):559-569. PubMed ID: 34586104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience.
    Lee YP; Jeong BH; Eun Y; Kang CI; Park S; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
    Eur J Cancer; 2021 Dec; 159():167-173. PubMed ID: 34753013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.